Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
. 2014 Aug;16(8):513.
doi: 10.1007/s11886-014-0513-4.

Biomarkers of Coronary Artery Disease: The Promise of the Transcriptome

Free PMC article

Biomarkers of Coronary Artery Disease: The Promise of the Transcriptome

Marten Antoon Siemelink et al. Curr Cardiol Rep. .
Free PMC article


The last years have witnessed tremendous technical advances in the field of transcriptomics that enable the simultaneous assessment of nearly all transcripts expressed in a tissue at a given time. These advances harbor the potential to gain a better understanding of the complex biological systems and for the identification and development of novel biomarkers. This article will review the current knowledge of transcriptomics biomarkers in the cardiovascular field and will provide an overview about the promises and challenges of the transcriptomics approach for biomarker identification.


Fig. 1
Fig. 1
Challenges in transcriptomic biomarker development. Figure depicts main steps in Biomarker discovery and development and associated challenges to overcome
Fig. 2
Fig. 2
Transcriptomics for biomarker discovery. Simplified schematic of relevant transcriptome interactions for current biomarker development. Large studies are required to elucidate the complex interactions of the genome and epigenome with the transcriptome and subsequently the proteome. Bullets denote contemporary techniques. eQTL, expression quantitative trait loci; meQTL, methylation quantitative trait loci; mRNA, messenger RNA; ncRNA, non-coding RNA

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles


    1. Shanthi Mendis PP, Bo Norrving. World Health Organization, World Heart Federation, World Stroke Organization. Global atlas on cardiovascular disease prevention and control: policies, strategies, and interventions.2011. 164 p.
    1. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. [European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)]. Giornale italiano di cardiologia. 2013 May;14(5):328-92. Linee guida europee sulla prevenzione delle malattie cardiovascolari nella pratica clinica (versione 2012). Quinta Task Force congiunta della Societa Europea di cardiologia e di altre societa sulla prevenzione delle malattie cardiovascolari nella pratica clinica (costituita da rappresentanti di nove societa e da esperti invitati). - PubMed
    1. Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Sr., Gibbons R, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Nov 12. - PubMed
    1. Zeller T, Blankenberg S. Blood-based gene expression tests: promises and limitations. Circ Cardiovasc Genet. 2013;6(2):139–40. doi: 10.1161/CIRCGENETICS.113.000149. - DOI - PubMed
    1. Crick FH. On protein synthesis. Symp Soc Exp Biol. 1958;12:138–63. - PubMed

Publication types